Daniel H. Geschwind

University of California
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (9)

Down syndrome is the most common genetic cause of intellectual disability, presenting with cognitive, learning, memory, and language deficits. The cellular and molecular mechanisms driving this disorder remain unclear, limited by a lack of systematic studies in the developing human brain. Here, we leveraged single-nucleus multi-omics to profile the mid-gestation neocortex in a cohort of 26 donors. We observed a reduction in neural progenitors and corticothalamic neurons and concomitant increase of intratelencephalic neurons, accompanied by accelerated time to neuronal specification. We uncovered widespread changes in gene expression, chromatin accessibility and cell interaction networks impacting neurogenesis, specification and maturation and gene-regulatory networks directing these processes, including those downstream of transcription factors encoded in chromosome 21. Finally, we identified cell-specific molecular pathways shared with other neurodevelopmental disorders as well as heritability enrichment of GWAS signals in altered chromatin. Together, our data revealed a cascade of molecular dysregulation outlining the earliest steps in Down syndrome, providing a foundation for future therapeutic targets.

Year:

2025

It has not previously been possible to investigate the fundamental relationship between axonal structure – which dictates action potential transmission – and human neuronal function in vivo . Here, we introduce a novel metric of axonal signal speed, estimated axonal latency (EAL), derived from the relationship between axonal diameter, myelination, and length measured via MRI. We validate EAL along two pathways of the face processing network by relating it to N170 latency, an electrophysiological marker of face processing speed measured via EEG. Our results show that EAL along these pathways predicts N170 latency specifically during face processing. Moreover, we demonstrate that individuals with and without autism rely upon different pathways, potentially providing a structural account for autism-related face processing differences. By establishing this relationship between EEG-based electrical function and MRI-based axonal microstructure, we provide a non-invasive, spatially detailed estimate of neuronal processing speed that can inform our understanding of brain function, development, and disorder. Teaser Estimated axonal latency is a non-invasive, spatially detailed measure of neuronal speed to inform brain function and disorder.

Year:

2025

Inferring cellular and molecular dynamics of multiple sclerosis (MS) lesions from postmortem tissue collected decades after onset is challenging. Using magnetic resonance image (MRI)–guided spatiotemporal RNA profiling in marmoset experimental autoimmune encephalitis (EAE), we mapped lesion dynamics and modeled molecular perturbations relevant to MS. Five distinct lesion microenvironments emerged, involving neuroglial responses, tissue destruction and repair, and brain border regulation. Before demyelination, MRI identified a high ratio of proton density–weighted signal to T 1 relaxation time, capturing early hypercellularity, and elevated astrocytic and ependymal senescence signals marked perivascular and periventricular areas that later became demyelination hotspots. As lesions expanded, concentric glial barriers formed, initially dominated by proliferating and diversifying microglia and oligodendrocyte precursors, later replaced by monocytes and lymphocytes. We highlight SERPINE1 + astrocytes as a signaling hub underlying lesion onset in both marmoset EAE and MS.

Year:

2025

MEF2C is a critical transcription factor in neurodevelopment, whose loss-of-function mutation in humans results in MEF2C haploinsufficiency syndrome (MHS), a severe form of autism spectrum disorder (ASD)/intellectual disability (ID). Despite prior animal studies of MEF2C heterozygosity to mimic MHS, MHS-specific mutations have not been investigated previously, particularly in a human context as hiPSCs afford. Here, for the first time, we use patient hiPSC-derived cerebrocortical neurons and cerebral organoids to characterize MHS deficits. Unexpectedly, we found that decreased neurogenesis was accompanied by activation of a micro-(mi)RNA-mediated gliogenesis pathway. We also demonstrate network-level hyperexcitability in MHS neurons, as evidenced by excessive synaptic and extrasynaptic activity contributing to excitatory/inhibitory (E/I) imbalance. Notably, the predominantly extrasynaptic (e)NMDA receptor antagonist, NitroSynapsin, corrects this aberrant electrical activity associated with abnormal phenotypes. During neurodevelopment, MEF2C regulates many ASD-associated gene networks, suggesting that treatment of MHS deficits may possibly help other forms of ASD as well.

Year:

2024

While voltage-gated potassium channels have critical roles in controlling neuronal excitability, they also have non-ion–conducting functions. Kv8.1, encoded by the KCNV1 gene, is a ‘silent’ ion channel subunit whose biological role is complex since Kv8.1 subunits do not form functional homotetramers but assemble with Kv2 to modify its ion channel properties. We profiled changes in ion channel expression in amyotrophic lateral sclerosis patient–derived motor neurons carrying a superoxide dismutase 1(A4V) mutation to identify what drives their hyperexcitability. A major change identified was a substantial reduction of KCNV1/Kv8.1 expression, which was also observed in patient-derived neurons with C9orf72 expansion. We then studied the effect of reducing KCNV1/Kv8.1 expression in healthy motor neurons and found it did not change neuronal firing but increased vulnerability to cell death. A transcriptomic analysis revealed dysregulated metabolism and lipid/protein transport pathways in KCNV1/Kv8.1-deficient motor neurons. The increased neuronal vulnerability produced by the loss of KCNV1/Kv8.1 was rescued by knocking down Kv2.2, suggesting a potential Kv2.2-dependent downstream mechanism in cell death. Our study reveals, therefore, unsuspected and distinct roles of Kv8.1 and Kv2.2 in amyotrophic lateral sclerosis–related neurodegeneration.

Year:

2024

Genomic profiling in postmortem brain from autistic individuals has consistently revealed convergent molecular changes. What drives these changes and how they relate to genetic susceptibility in this complex condition are not well understood. We performed deep single-nucleus RNA sequencing (snRNA-seq) to examine cell composition and transcriptomics, identifying dysregulation of cell type–specific gene regulatory networks (GRNs) in autism spectrum disorder (ASD), which we corroborated using single-nucleus assay for transposase-accessible chromatin with sequencing (snATAC-seq) and spatial transcriptomics. Transcriptomic changes were primarily cell type specific, involving multiple cell types, most prominently interhemispheric and callosal-projecting neurons, interneurons within superficial laminae, and distinct glial reactive states involving oligodendrocytes, microglia, and astrocytes. Autism-associated GRN drivers and their targets were enriched in rare and common genetic risk variants, connecting autism genetic susceptibility and cellular and circuit alterations in the human brain.

Year:

2024

The pathophysiological mechanisms driving disease progression of frontotemporal lobar degeneration (FTLD) and corresponding biomarkers are not fully understood. We leveraged aptamer-based proteomics (> 4,000 proteins) to identify dysregulated communities of co-expressed cerebrospinal fluid proteins in 116 adults carrying autosomal dominant FTLD mutations ( C9orf72 , GRN , MAPT ) compared to 39 noncarrier controls. Network analysis identified 31 protein co-expression modules. Proteomic signatures of genetic FTLD clinical severity included increased abundance of RNA splicing (particularly in C9orf72 and GRN ) and extracellular matrix (particularly in MAPT ) modules, as well as decreased abundance of synaptic/neuronal and autophagy modules. The generalizability of genetic FTLD proteomic signatures was tested and confirmed in independent cohorts of 1) sporadic progressive supranuclear palsy-Richardson syndrome and 2) frontotemporal dementia spectrum syndromes. Network-based proteomics hold promise for identifying replicable molecular pathways in adults living with FTLD. ‘Hub’ proteins driving co-expression of affected modules warrant further attention as candidate biomarkers and therapeutic targets.

Year:

2024

Genome-wide association studies (GWAS) and expression analyses implicate noncoding regulatory regions as harboring risk factors for psychiatric disease, but functional characterization of these regions remains limited. We performed capture STARR-sequencing of over 78,000 candidate regions to identify active enhancers in primary human neural progenitor cells (phNPCs). We selected candidate regions by integrating data from NPCs, prefrontal cortex, developmental timepoints, and GWAS. Over 8,000 regions demonstrated enhancer activity in the phNPCs, and we linked these regions to over 2,200 predicted target genes. These genes are involved in neuronal and psychiatric disease-associated pathways, including dopaminergic synapse, axon guidance, and schizophrenia. We functionally validated a subset of these enhancers using mutation STARR-sequencing and CRISPR deletions, demonstrating the effects of genetic variation on enhancer activity and enhancer deletion on gene expression. Overall, we identified thousands of highly active enhancers and functionally validated a subset of these enhancers, improving our understanding of regulatory networks underlying brain function and disease.

Year:

2024

Predicting the function of noncoding variation is a major challenge in modern genetics. In this study, we used massively parallel reporter assays to screen 5706 variants identified from genome-wide association studies for both Alzheimer’s disease (AD) and progressive supranuclear palsy (PSP), identifying 320 functional regulatory variants (frVars) across 27 loci, including the complex 17q21.31 region. We identified and validated multiple risk loci using CRISPR interference or excision, including complement 4 ( C4A ) and APOC1 in AD and PLEKHM1 and KANSL1 in PSP. Functional variants disrupt transcription factor binding sites converging on enhancers with cell type–specific activity in PSP and AD, implicating a neuronal SP1-driven regulatory network in PSP pathogenesis. These analyses suggest that noncoding genetic risk is driven by common genetic variants through their aggregate activity on specific transcriptional programs.

Year:

2022

Collaborators (38)

John Darrell Van Horn

Professor

University of Virginia

UNITED STATES
View details

Doug Galasko

UC San Diego Health System

UNITED STATES
View details

Benjamin Newman

University of Virginia

UNITED STATES
View details

Mark Gerstein

Yale University

UNITED STATES
View details

Shafali Jeste

Chair of Pediatrics

University of California, Los Angeles

UNITED STATES
View details

Lawrence Honig

Professor, Director of NYS Center of Excellence for Alzheimer's Disease, Deputy Director Alzheimer's Disease Research Center

Columbia University Irving Medical Center

UNITED STATES
View details

Maria Carmela Tartaglia

University of Toronto

CANADA
View details

Nicholas Seyfried

Professor

Emory University

UNITED STATES
View details

Jason Liu

Assistant Professor

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Luis de la Torre-Ubieta

Assistant Professor In Residence

University of California, Los Angeles

UNITED STATES
View details

Allison Jack

Assistant Professor

George Mason University

UNITED STATES
View details

Ging-Yuek Hsiung

The University of British Columbia

CANADA
View details

Erik Roberson

University of Alabama, Tuscaloosa

UNITED STATES
View details

Jason L Stein

Associate Professor

University of North Carolina at Chapel Hill

UNITED STATES
View details

Oskar Hansson

Full professor of Neurology

Lund University

SWEDEN
View details

Erik Johnson

Assistant Professor

Emory University School of Medicine

UNITED STATES
View details

Gregory Day

Associate Professor, Consultant

Mayo Clinic

UNITED STATES
View details

Jennifer Yokoyama

University of California

UNITED STATES
View details

Dorothy Schafer

University of Massachusetts Chan Medical School

UNITED STATES
View details

Meghan H. Puglia

-

UNITED STATES
View details

Nupur Ghoshal

Professor

Washington University in St. Louis

UNITED STATES
View details

Eric Dammer

Scientist, Bioinformatics

Emory University

UNITED STATES
View details

Vardan Arutiunian

CHU Sainte-Justine

CANADA
View details

Stuart Lipton

Professor

Scripps Research Institute

UNITED STATES
View details

Susan Bookheimer

Professor

University of California, Los Angeles

UNITED STATES
View details

Michael Gandal

William & Noreen Hetznecker Associate Professor

University of Pennsylvania

UNITED STATES
View details

Emily Neuhaus

Associate Professor

University of Washington

UNITED STATES
View details

Irene Litvan

Professor

University of California, San Diego

UNITED STATES
View details

Natalia M. Kleinhans

University of Washington

UNITED STATES
View details

Sara Jane Webb

Professor

Seattle Children's Research Institute

UNITED STATES
View details

Jing Zhang

Associate Professor

University of California

UNITED STATES
View details

Paweł Stankiewicz

Baylor College of Medicine

UNITED STATES
View details

Mario Mendez

Professor

University of California, Los Angeles

UNITED STATES
View details

adam naples

Assistant Professor

Yale University School of Medicine

UNITED STATES
View details

Lea T. Grinberg

-

UNITED STATES
View details

Allison Snyder

Assistant Professor

University of Pennsylvania

UNITED STATES
View details

Salvatore Spina

Associate Professor

University of California, San Francisco

UNITED STATES
View details

Adam M. Staffaroni

University of California

UNITED STATES
View details